Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of CAP7.1 in Adult Patients With Refractory Malignancies: Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Biliary Carcinoma (PIITCAP)

NCT02094560 is registered in ClinicalTrials.gov with CellAct Pharma GmbH as lead sponsor.

NCT NCT02094560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02094560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of CAP7.1 in Adult Patients With Refractory Malignancies: Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Biliary Carcinoma (PIITCAP)
Lead sponsor
CellAct Pharma GmbH
Phase
Phase 2
Overall status
Terminated
Start date
November 8, 2011
Completion date
April 10, 2017
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endstage solid carcinomas in adults